SHR-A1811 + SHR-1316 + capecitabine + oxaliplatin

This is a combination regimen consisting of four agents: - **SHR-A1811** (also known as trastuzumab rezetecan) is an antibody-drug conjugate targeting HER2 (human epidermal growth factor receptor 2). It consists of a monoclonal antibody linked to a cytotoxic payload, designed to selectively deliver chemotherapy to HER2-expressing tumor cells. It has demonstrated antitumor activity and acceptable tolerability in advanced HER2-mutant non-small cell lung cancer and HER2-positive breast cancer[2][3][4][5]. - **SHR-1316** is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and its receptor PD-1, thereby enhancing T-cell mediated immune responses against tumors[8]. - **Capecitabine** is an oral prodrug of 5-fluorouracil, a small molecule chemotherapeutic agent that inhibits DNA synthesis by interfering with thymidylate synthase. - **Oxaliplatin** is a platinum-based small molecule chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. This combination leverages targeted therapy (HER2-directed ADC), immunotherapy (PD-L1 blockade), and cytotoxic chemotherapy for potential synergistic effects in treating cancers such as HER2-positive or HER2-mutant solid tumors.

Other names

SHR-A1811 + SHR-1316 + XELOXSHR-A1811 + SHR-1316 + CAPOX